​

AbbVie (ABBV) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

AbbVie Revenue Highlights

0

Latest Revenue (Q)

$15.42B

Main Segment (Y)

SKYRIZI

Main Geography (Y)

UNITED STATES

AbbVie Revenue by Period

AbbVie Revenue by Year

DateRevenueChange
2024-12-31--100.00%
2023-12-31$54.32B-6.44%
2022-12-31$58.05B3.30%
2021-12-31$56.20B22.69%
2020-12-31$45.80B37.69%
2019-12-31$33.27B1.57%
2018-12-31$32.75B16.08%
2017-12-31$28.22B10.06%
2016-12-31$25.64B12.16%
2015-12-31$22.86B14.52%
2014-12-31$19.96B6.23%
2013-12-31$18.79B2.23%
2012-12-31$18.38B5.37%
2011-12-31$17.44B11.55%
2010-12-31$15.64B10.02%
2009-12-31$14.21B-

AbbVie generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

AbbVie Revenue by Quarter

DateRevenueChange
2025-06-30$15.42B15.59%
2025-03-31$13.34B-11.65%
2024-12-31$15.10B4.44%
2024-09-30$14.46B-0.01%
2024-06-30$14.46B17.48%
2024-03-31$12.31B-13.92%
2023-12-31$14.30B2.69%
2023-09-30$13.93B0.45%
2023-06-30$13.87B13.42%
2023-03-31$12.22B-19.15%
2022-12-31$15.12B2.09%
2022-09-30$14.81B1.57%
2022-06-30$14.58B7.72%
2022-03-31$13.54B-9.06%
2021-12-31$14.89B3.79%
2021-09-30$14.34B2.74%
2021-06-30$13.96B7.29%
2021-03-31$13.01B-6.12%
2020-12-31$13.86B7.41%
2020-09-30$12.90B23.76%
2020-06-30$10.43B20.95%
2020-03-31$8.62B-0.98%
2019-12-31$8.70B2.65%
2019-09-30$8.48B2.71%
2019-06-30$8.26B5.45%
2019-03-31$7.83B-5.74%
2018-12-31$8.30B0.84%
2018-09-30$8.24B-0.51%
2018-06-30$8.28B4.34%
2018-03-31$7.93B2.52%
2017-12-31$7.74B10.64%
2017-09-30$7.00B0.73%
2017-06-30$6.94B6.21%
2017-03-31$6.54B-3.80%
2016-12-31$6.80B5.66%
2016-09-30$6.43B-0.31%
2016-06-30$6.45B8.29%
2016-03-31$5.96B-6.91%
2015-12-31$6.40B7.67%
2015-09-30$5.94B8.57%
2015-06-30$5.47B8.63%
2015-03-31$5.04B-7.56%
2014-12-31$5.45B8.63%
2014-09-30$5.02B1.89%
2014-06-30$4.93B7.96%
2014-03-31$4.56B-10.72%
2013-12-31$5.11B9.73%
2013-09-30$4.66B-0.72%
2013-06-30$4.69B8.39%
2013-03-31$4.33B-16.84%
2012-12-31$5.21B15.48%
2012-09-30$4.51B0.33%
2012-06-30$4.49B7.67%
2012-03-31$4.17B-14.21%
2011-12-31$4.86B10.33%
2011-09-30$4.41B3.14%
2011-06-30$4.27B9.69%
2011-03-31$3.90B-

AbbVie generated $15.42B in revenue during Q2 2025, up 15.59% compared to the previous quarter, and up 125.29% compared to the same period a year ago.

AbbVie Revenue Breakdown

AbbVie Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Duodopa$447.00M$468.00M$458.00M--
Other Neuroscience$338.00M$276.00M$475.00M--
Qulipta$658.00M$408.00M---
Ubrelvy$1.01B$815.00M---
Vraylar$3.27B$2.76B$2.04B--
VENCLEXTA$2.58B$2.29B$2.01B--
Imbruvica$3.35B$3.60B$4.57B--
Restasis$224.00M$436.00M$666.00M--
Ozurdex$494.00M$472.00M---
Other Eye Care$847.00M$803.00M$1.18B--
Lumigan/Ganfort$429.00M$432.00M$514.00M--
Alphagan/Combigan$248.00M$272.00M$346.00M--
Botox Therapeutic$3.28B$2.99B$2.72B--
SKYRIZI$11.72B$7.76B$5.17B--
RINVOQ$5.97B$3.97B$2.52B--
H U M I R A$8.99B$14.40B$21.24B--
Other Aesthetics$1.28B$1.23B$1.29B--
Juvederm Collection$1.18B$1.38B$1.43B--
Botox Cosmetic$2.72B$2.68B$2.62B--
Other Products$3.03B$3.04B$4.14B$2.67B$2.92B
MAVYRET$1.31B$1.43B$1.54B--
Linzess/Constella$954.00M$1.11B$1.03B--

AbbVie's latest annual revenue breakdown by segment (product or service), as of Dec 24: SKYRIZI (21.57%), H U M I R A (16.55%), RINVOQ (10.99%), Imbruvica (6.16%), Botox Therapeutic (6.04%), Vraylar (6.01%), Other Products (5.58%), Botox Cosmetic (5.01%), VENCLEXTA (4.75%), MAVYRET (2.41%), Other Aesthetics (2.35%), Juvederm Collection (2.17%), Ubrelvy (1.85%), Linzess/Constella (1.76%), Other Eye Care (1.56%), Qulipta (1.21%), Ozurdex (0.91%), Duodopa (0.82%), Lumigan/Ganfort (0.79%), Other Neuroscience (0.62%), Alphagan/Combigan (0.46%), and Restasis (0.41%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
Duodopa$97.00M$96.00M$221.00M$111.00M$115.00M$115.00M$118.00M$117.00M------------
Botox Therapeutic$928.00M$866.00M$1.69B$848.00M$748.00M$776.00M$748.00M$748.00M------------
SKYRIZI$4.42B$3.42B$6.50B$3.21B$2.01B$2.39B$2.13B$1.88B------------
RINVOQ$2.03B$1.72B$3.26B$1.61B$1.09B$1.25B$1.11B$918.00M------------
H U M I R A$1.18B$1.12B$4.50B$2.23B$2.27B$3.30B$3.55B$4.01B------------
Ozurdex$125.00M$123.00M$244.00M$119.00M$131.00M$118.00M$120.00M$119.00M------------
Other Eye Care$250.00M$217.00M$440.00M$207.00M$200.00M$181.00M$207.00M$215.00M------------
Lumigan/Ganfort$103.00M$106.00M$222.00M$116.00M$91.00M$92.00M$91.00M$119.00M------------
Alphagan/Combigan$36.00M$60.00M$127.00M$62.00M$59.00M$66.00M$70.00M$65.00M------------
Other Aesthetics$327.00M$315.00M$650.00M$310.00M$319.00M$319.00M$298.00M$331.00M------------
Juvederm Collection$260.00M$231.00M$622.00M$258.00M$297.00M$334.00M$321.00M$368.00M------------
Botox Cosmetic$692.00M$556.00M$1.42B$671.00M$633.00M$718.00M$620.00M$685.00M------------
Other Products$603.00M$747.00M$1.56B$726.00M$744.00M$821.00M$782.00M$741.00M$691.00M$992.00M$925.00M$1.01B$1.21B$594.00M$547.00M$640.00M$892.00M$951.00M$829.00M$590.00M
MAVYRET$375.00M$306.00M$660.00M$302.00M$349.00M$309.00M$370.00M$387.00M------------
Linzess/Constella$258.00M$148.00M$454.00M$234.00M$266.00M$283.00M$288.00M$278.00M------------
VENCLEXTA$691.00M$665.00M$1.29B$677.00M$614.00M$589.00M$590.00M$571.00M------------
Imbruvica$754.00M$738.00M$1.68B$828.00M$838.00M$903.00M$908.00M$907.00M------------
Vraylar$900.00M$765.00M$1.70B$875.00M$694.00M$789.00M$751.00M$658.00M------------
Ubrelvy$338.00M$240.00M$534.00M$269.00M$203.00M$234.00M$233.00M$196.00M------------
Qulipta$267.00M$193.00M$351.00M$176.00M$131.00M$180.00M$132.00M$96.00M------------
Other Neuroscience$55.00M$59.00M$180.00M$84.00M$74.00M$66.00M$61.00M$70.00M------------
Restasis--$146.00M$21.00M$57.00M$128.00M$117.00M$99.00M------------

AbbVie's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: SKYRIZI (30.11%), RINVOQ (13.81%), H U M I R A (8.03%), Botox Therapeutic (6.32%), Vraylar (6.13%), Imbruvica (5.13%), Botox Cosmetic (4.71%), VENCLEXTA (4.70%), Other Products (4.10%), MAVYRET (2.55%), Ubrelvy (2.30%), Other Aesthetics (2.23%), Qulipta (1.82%), Juvederm Collection (1.77%), Linzess/Constella (1.76%), Other Eye Care (1.70%), Ozurdex (0.85%), Lumigan/Ganfort (0.70%), Duodopa (0.66%), Other Neuroscience (0.37%), and Alphagan/Combigan (0.25%).

AbbVie Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24Dec 23Dec 22Dec 21Dec 20
CHINA$917.00M$950.00M$912.00M$857.00M$471.00M
CANADA$1.09B$1.08B$1.16B$1.40B$1.16B
BRAZIL$464.00M$439.00M$430.00M$368.00M$406.00M
AUSTRALIA$463.00M$472.00M$508.00M$533.00M$527.00M
UNITED STATES$43.03B$41.88B---
SPAIN$528.00M$501.00M$506.00M$519.00M$453.00M
Other Countries$5.45B$5.04B$4.84B$4.76B$3.98B
JAPAN$1.12B$1.01B$956.00M$1.09B$1.20B
ITALY$511.00M$484.00M$444.00M$506.00M$379.00M
GERMANY$1.47B$1.27B$1.34B$1.22B$1.05B
FRANCE$776.00M$780.00M$787.00M$936.00M$797.00M

AbbVie's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (77.10%), Other Countries (9.76%), GERMANY (2.62%), JAPAN (2.01%), CANADA (1.95%), CHINA (1.64%), FRANCE (1.39%), SPAIN (0.95%), ITALY (0.92%), BRAZIL (0.83%), and AUSTRALIA (0.83%).

Quarterly Revenue by Country

CountryJun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
UNITED STATES$3.84B$3.36B$38.48B$2.78B$1.77B$19.95B$3.02B$10.19B$171.00M$193.00M$190.00M$203.00M$169.00M$56.00M$57.00M$50.00M$46.00M$73.00M$74.00M$34.00M
Non-US$580.00M$9.98B$462.00M$499.00M$527.00M$2.93B$193.00M$187.00M$193.00M$195.00M$211.00M--$2.00M-$1.00M$6.00M$1.00M--

AbbVie's latest quarterly revenue breakdown by geography, as of Jun 25: UNITED STATES (86.89%), and Non-US (13.11%).

AbbVie Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
MRKMerck$64.17B$15.81B
PFEPfizer$63.63B$14.65B
JNJJohnson & Johnson$61.35B$23.74B
BMYBristol-Myers Squibb$48.30B$12.27B
LLYEli Lilly and$45.04B$15.56B
AMGNAmgen$33.42B$9.18B
GILDGilead Sciences$28.75B$6.67B
ABBVAbbVie-$15.42B

ABBV Revenue FAQ

What is AbbVie’s yearly revenue?

AbbVie's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $54.32B, representing a decrease of -6.44% compared to 2022. ABBV's yearly revenue for 2022 was $58.05B, representing an increase of 3.30% compared to 2021.

What is AbbVie’s quarterly revenue?

AbbVie's quarterly revenue for Q2 2025 was $15.42B, a 15.59% increase from the previous quarter (Q1 2025), and a 6.65% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $13.34B, a -11.65% decrease from the previous quarter (Q4 2024), and a 8.39% increase year-over-year (Q1 2024). ABBV's quarterly revenue for Q4 2024 was $15.1B, a 4.44% increase from the previous quarter (Q3 2024), and a 5.60% increase year-over-year (Q4 2023).

What is AbbVie’s revenue growth rate?

AbbVie's revenue growth rate for the last 3 years (2022-2024) was -100.00%, and for the last 5 years (2020-2024) was -100.00%.

What are AbbVie’s revenue streams?

AbbVie's revenue streams in c 24 are Duodopa, Other Neuroscience, Qulipta, Ubrelvy, Vraylar, VENCLEXTA, Imbruvica, Restasis, Ozurdex, Other Eye Care, Lumigan/Ganfort, Alphagan/Combigan, Botox Therapeutic, SKYRIZI, RINVOQ, H U M I R A, Other Aesthetics, Juvederm Collection, Botox Cosmetic, Other Products, MAVYRET, and Linzess/Constella. Duodopa generated $447M in revenue, accounting 0.82% of the company's total revenue, down -4.49% year-over-year. Other Neuroscience generated $338M in revenue, accounting 0.62% of the company's total revenue, up 22.46% year-over-year. Qulipta generated $658M in revenue, accounting 1.21% of the company's total revenue, up 61.27% year-over-year. Ubrelvy generated $1.01B in revenue, accounting 1.85% of the company's total revenue, up 23.44% year-over-year. Vraylar generated $3.27B in revenue, accounting 6.01% of the company's total revenue, up 18.41% year-over-year. VENCLEXTA generated $2.58B in revenue, accounting 4.75% of the company's total revenue, up 12.89% year-over-year. Imbruvica generated $3.35B in revenue, accounting 6.16% of the company's total revenue, down -6.92% year-over-year. Restasis generated $224M in revenue, accounting 0.41% of the company's total revenue, down -48.62% year-over-year. Ozurdex generated $494M in revenue, accounting 0.91% of the company's total revenue, up 4.66% year-over-year. Other Eye Care generated $847M in revenue, accounting 1.56% of the company's total revenue, up 5.48% year-over-year. Lumigan/Ganfort generated $429M in revenue, accounting 0.79% of the company's total revenue, down -0.69% year-over-year. Alphagan/Combigan generated $248M in revenue, accounting 0.46% of the company's total revenue, down -8.82% year-over-year. Botox Therapeutic generated $3.28B in revenue, accounting 6.04% of the company's total revenue, up 9.76% year-over-year. SKYRIZI generated $11.72B in revenue, accounting 21.57% of the company's total revenue, up 50.95% year-over-year. RINVOQ generated $5.97B in revenue, accounting 10.99% of the company's total revenue, up 50.44% year-over-year. H U M I R A generated $8.99B in revenue, accounting 16.55% of the company's total revenue, down -37.57% year-over-year. Other Aesthetics generated $1.28B in revenue, accounting 2.35% of the company's total revenue, up 3.65% year-over-year. Juvederm Collection generated $1.18B in revenue, accounting 2.17% of the company's total revenue, down -14.59% year-over-year. Botox Cosmetic generated $2.72B in revenue, accounting 5.01% of the company's total revenue, up 1.42% year-over-year. Other Products generated $3.03B in revenue, accounting 5.58% of the company's total revenue, down -0.10% year-over-year. MAVYRET generated $1.31B in revenue, accounting 2.41% of the company's total revenue, down -8.32% year-over-year. Linzess/Constella generated $954M in revenue, accounting 1.76% of the company's total revenue, down -13.90% year-over-year.

What is AbbVie’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of AbbVie was SKYRIZI. This segment made a revenue of $11.72B, representing 21.57% of the company's total revenue.